This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a star-studded biotechnology startup that raised more than $1 billion in venture funding, said Wednesday it has secured $381 million more through an initial public offering. The California biotech sold over 21 million shares at $18 apiece, far more than it initially set out to sell when it set terms for its offering last week. Shares will ...

By Sriparna Roy and Christy Santhosh Jan 14 (Reuters) - Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies are expected to go public amid a renewed deal-making appetite and a lower interest rate scenario, even as they come ​to terms with the political and regulatory environment. Amid President Donald Trump's policy shifts, the most disruptive scenarios for healthcare now appear less ‌likely, helping restore a degree of confidence after tariff threats, funding cuts and s ...